BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2667111)

  • 1. Clinical efficacy of ciprofloxacin in lower respiratory tract infections.
    Pedersen SS
    Scand J Infect Dis Suppl; 1989; 60():89-97. PubMed ID: 2667111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.
    Peloquin CA; Cumbo TJ; Nix DE; Sands MF; Schentag JJ
    Arch Intern Med; 1989 Oct; 149(10):2269-73. PubMed ID: 2508586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of fluoroquinolones in lower respiratory tract infections.
    Vellend H
    Clin Invest Med; 1989 Feb; 12(1):39-43. PubMed ID: 2920482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ciprofloxacin: an oral quinolone for the treatment of infections with gram-negative pathogens. Committee on Antimicrobial Agents. Canadian Infectious Disease Society.
    Louie TJ
    CMAJ; 1994 Mar; 150(5):669-76. PubMed ID: 8313286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis.
    Stutman HR; Shalit I; Marks MI; Greenwood R; Chartrand SA; Hilman BC
    Am J Med; 1987 Apr; 82(4A):142-5. PubMed ID: 3555028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ciprofloxacin: an update on clinical experience.
    Arcieri G; Griffith E; Gruenwaldt G; Heyd A; O'Brien B; Becker N; August R
    Am J Med; 1987 Apr; 82(4A):381-6. PubMed ID: 3555063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled, comparative study of ciprofloxacin versus ampicillin in treatment of bacterial respiratory tract infections.
    Wollschlager CM; Raoof S; Khan FA; Guarneri JJ; LaBombardi V; Afzal Q
    Am J Med; 1987 Apr; 82(4A):164-8. PubMed ID: 3555030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ciprofloxacin and norfloxacin, two fluoroquinolone antimicrobials.
    Nix DE; DeVito JM
    Clin Pharm; 1987 Feb; 6(2):105-17. PubMed ID: 3311572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective randomized clinical trials of new quinolones versus beta-lactam antibiotics in lower respiratory tract infections.
    Lode H; Wiley E; Olschewski P; Sievers H; Wintermantel M; Baetz R; Lebahn K; Reinke M; Wagner J; Borner K
    Scand J Infect Dis Suppl; 1990; 68():50-5. PubMed ID: 2218423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis.
    Goldfarb J; Stern RC; Reed MD; Yamashita TS; Myers CM; Blumer JL
    Am J Med; 1987 Apr; 82(4A):174-9. PubMed ID: 3555032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of ciprofloxacin in the treatment of patients with respiratory tract infections in Japan.
    Kobayashi H
    Am J Med; 1987 Apr; 82(4A):169-73. PubMed ID: 3555031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of oral ciprofloxacin in the treatment of serious respiratory infections.
    Fass RJ
    Am J Med; 1987 Apr; 82(4A):202-7. PubMed ID: 3555037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
    Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emergence of resistance to beta-lactam antibiotics during treatment of Pseudomonas aeruginosa lower respiratory tract infections: is combination therapy the solution?
    Nichols L; Maki DG
    Chemioterapia; 1985 Feb; 4(1):102-9. PubMed ID: 3986938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ciprofloxacin by the intravenous route in the treatment of respiratory infections].
    Mangiarotti P; Manara G; Bianchi L; Piccioni PD; Grassi C
    G Ital Chemioter; 1989; 36(1-3):89-94. PubMed ID: 2488917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activity of ciprofloxacin and other unrelated antimicrobials against bacterial respiratory tract pathogens.
    Felmingham D; Robbins MJ; Baskerville AJ; Sanghrajka MD; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1989; 15(2):59-62. PubMed ID: 2737080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Focus on oral ciprofloxacin; clinical and economic considerations.
    Pastel D
    Hosp Pharm; 1989 Oct; 24(10):814-20, 823-6, 842. PubMed ID: 10295899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The clinical manifestation and drug sensitive tests of lower respiratory tract infection by enterobacter cloacae. The Pulmonary Infection and Fibrosis Group, Thoracic Society Shanghai Medical Association].
    Zhonghua Jie He He Hu Xi Za Zhi; 1997 Aug; 20(4):208-11. PubMed ID: 10072803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections.
    Nix DE; Sands MF; Peloquin CA; Vari AJ; Cumbo TJ; Vance JW; Fracasso JE; Schentag JJ
    Am J Med; 1987 Apr; 82(4A):352-6. PubMed ID: 3555060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.